INTRODUCTION:

There is presently no indication that Omicron causes more severe illness than Delta, either among naive or immunized people. Even if pre-existing SARS-CoV-2 antibodies are only marginally effective in preventing Omicron infection, anamnestic responses and cellular immunity are expected to be effective in preventing severe illness¹.

Antibodies neutralize Omicron variants:

Scientists have found antibodies that neutralize Omicron and other variants. These antibodies attack parts of the viral spike protein that don't change as the virus evolves. The spike protein in the omicron form has 37 mutations. It employs an exceptionally large number of mutations to latch onto and penetrate cells. The latest discoveries may pave the way for more efficient immunizations. Scientists may be able to use the knowledge to combat the virus's ongoing development. These vaccinations will protect against not just the omicron version, but also any future variants that may occur².

Scientists believe that these mutations are to blame for the variant's fast dissemination. Omicron has infected both vaccinated and unvaccinated persons, reinfecting those who have already been afflicted. Some experts believe that omicron's enormous number of mutations developed over time because to a protracted infection. It's possible that the host was a human with a functioning immune system. Another possibility is that the virus moved from humans to animal species and back³.

Researchers used a crippled, non-replicating virus to test the impact of these changes. This is referred to as a pseudovirus, and it has the ability to create spike proteins on its surface. The researchers initially looked at the different spike protein variants and how they were able to attach to protein on the cell surface. The angiotensin converting enzyme-2 (ACE2) receptor is the name of this protein. From the beginning of the pandemic, they discovered that the omicron variant spike protein could bind 2.4 times better than spike protein. Antibodies from persons who had previously been infected with other strains or gad who had received a vaccination were also studied. They discovered that they all had a diminished ability to prevent Omicron infection^4,5.

Antibodies from previously infected patients and those who had received the Sputnik V or Sinopharm vaccines, as well as a single dose of Johnson & Johnson, exhibited little or no capacity to inhibit – or "neutralize" – the omicron variant's entrance into cells. Antibodies from patients who had received two doses of the Moderna, Pfizer/BioNTech, and AstraZeneca vaccines retained some neutralizing action, but at a far lower level than any other variety⁶.

Third dose boosts the neutralizing antibodies:

A research found that two doses of BNT162b2 or CoronaVac vaccines generate low neutralizing antibodies against the Omicron form even 3-5 weeks after immunization. Following two doses of either BNT162b2 or CoronaVac, homologous or heterologous BNT162b2 booster doses enhance neutralizing antibody levels against the Omicron variant at 3-5 weeks post-booster dose. Most participants did not develop neutralizing antibodies to Omicron after three doses of CoronaVac. In response to the expansion of Omicron, nations that largely employ CoronaVac vaccines may need to consider mRNA vaccination boosters, according to our data. CoronaVac, on the other hand, has been found to elicit a broader spectrum of virus-specific T-cell responses, which might compensate for the loss of neutralizing antibody protection⁷.

The importance of monoclonal antibodies:

Six mnoclonal antivodies (Bamlanivimab, Etesevimab, Casirivimab, Imdevimab, Tixagevimab, and Regdanvimab) were shown to be ineffective against Omicron in another investigation. The IC50 of two additional antibodies (Cilgavimab and Andintrevimab) was increased by around 20 times. Omicron's mutations had a less impact on Sotrovimab, with an IC50 rise of only three times. Sera from vaccinated people who were collected 5 months after receiving two doses of Pfizer or AstraZeneca vaccine were only marginally neutralized by Omicron, according to the research. Sera from convalescent people six or twelve months after infection hardly neutralized Omicron or did not neutralize it at all^8,9.

Treatment techniques based on antibodies must be quickly modified to Omicron. Most low-income nations have a poor vaccination rate, which presumably aids SARS-CoV-2 dissemination and evolution. A booster dosage enhances the quality and quantity of the humoral immune response and is linked to good protection against the disease's severe manifestations. To stop the spread of the virus, vaccinations and boosters must be distributed quickly all around the world. It has been recommended that the present pharmacopoeia should be updated and completed, particularly in the areas of vaccinations and monoclonal antibodies^10,11.

In the coming weeks or months, Omicron is projected to overtake the dominating Delta lineage. The sensitivity of its humoral immune response is poorly understood. Omicron appears to be less sensitive to specific monoclonal and polyclonal antibodies, according to recent preprints, but CD8+ T-cell epitopes previously identified in other variations appear to be preserved in Omicron.

CONCLUSIONS:

Because antibodies can neutralize so many distinct variations of the virus by recognizing conserved sites, vaccinations and antibody therapies that target these regions might be successful against a wide range of mutations. Immunogenicity studies allow for quick evaluations of vaccines' potential protective effects against new variations, but field investigations of vaccination efficacy are urgently needed.

REFERENCES:

1. Dejnirattisai W. et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. medRxiv. 2021; 2012.2010.21267534, https://doi.org/10.1101/2021.12.10.21267534.

2. Aggarwal A. et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv. 2021; 2012.2014.21267772. https://doi.org/10.1101/2021.12.14.21267772.

3. Dawood A, Altobje M, and Alnori H. Compatibility of the Ligand Binding Sites in the Spike Glycoprotein of COVID-19 with those in the Aminopeptidase and the Caveolins 1, 2 Proteins. Res J Pharm Tech. 2021; 14(9): 4760-4766. doi:10.52711/0974-360X.2021.00828.

4. Redd A. D. et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. Preprint at Biorxiv. https://doi.org/10.1101/2021.12.06.471446.

5. Dawood A, Altobje M, and Alrassam Z. Molecular Docking of SARS-CoV-2 Nucleocapsid Protein with Angiotensin-Converting Enzyme II. Mikrobio Zhu. 2021; 83(2):82-92. doi: 10.15407/microbiolj83.02.082.

6. Planas D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Med. 201; 27, 917-924. https://doi.org/10.1038/s41591-021-01318-5.

7. Dawood A. Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence. Microb Path. 2022; 154 (105400). https://doi.org/10.1016/j.micpath.2022.105400.

8. Rappazzo G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021; 371, 823-829. https://doi.org/10.1126/science.abf4830.

9. Jones E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Trans Med. 2021; 13, eabf1906, https://doi.org/10.1126/scitranslmed.abf1906.

10. Sun S, Gu H, Cao L, Chen Q, Ye Q, and Yang G, et al. Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. Nat Commun. 2021; 12, 5654.

11. Telenti A, Arvin A, Corey L, Corti D, Diamond MS, and Garcia-Sastre A, et al. After the pandemic: perspectives on the future trajectory of COVID-19. Nature. 2021; 596, 495e504.

Received on 12.02.2022 Modified on 04.03.2022

Research J. Science and Tech. 2022; 14(2):95-97.

DOI: 10.52711/2349-2988.2022.00015